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Aim: Antiviral drug-resistant HBV mutants are complex and currently partly understood. This study was performed
to analyze the profile of hepatitis B virus (HBV) resistance mutations against nucleos(t)ide analogues (NAs) in
patients with chronic hepatitis B (CHB).
Methods: This was a population-based cross-sectional study. Serum samples of 179 patients with virological
breakthrough undergoing different NAs treatment were obtained between January 2008 and December 2012. The
HBV reverse transcriptase region was sequenced and the following NAs-resistant changes including rtL80, rtI169,
rtV173, rtL180, rtA181, rtT184, rtA194, rtS202, rtM204, rtN236 and rtM250 were analyzed.
Results: In this cohort, 21.2% (38/179) were genotypes B and 78.8% (141/179) were genotypes C; and 89.4% (160/
179) of them detected NAs-resistant mutations. The prevalence of HBV mutations at rtM204 was 93.0% (106/114)
in patients with lamivudine (LAM) or telbivudine (LdT)-based therapies, and that of rtN236 mutations was 76.1%
(35/46) in patients with adefovir dipivoxil (ADV)-based therapies. Among LAM/LdT based therapies, HBV rtM204I
was significantly associated with HBV rtL80I/V mutations [rtM204I+rtL80I/V (50.0%, 32/64) vs. rtM204V+rtL80I/V
(27.3%,9/33), P=0.032]; while the HBV rtM204V mutations was significantly associated with HBV rtL180M mutations
[rtM204V+rtL180M (100%, 33/33) vs. rtM204I+rtL180M (60.9%, 39/64), P<0.001]. Additionally, HBV rtA181 mutations
were observed in 19.3% (22/114) of patients with LAM/LdT-based therapy and 23.9% (11/46) of patients with ADV-
based therapy.
Conclusions: Majority of virological breakthrough is associated with NAs-resistant HBV, and the mutation patterns
of NAs-resistant HBV are complicated in real clinical practice.
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For the ability to inhibit the activity of hepatitis B virus
(HBV) reverse transcriptase (RT), nucleos(t)ide ana-
logues (NAs) such as lamivudine (LAM), adefovir dipi-
voxil (ADV), entecavir (ETV) and telbivudine (LdT) are
approved for the treatment of chronic hepatitis B (CHB)
in China [1,2]. However, with wide-scale and long-term
use of NAs against HBV, more attention has been focused
on the risk of development of NAs resistance; and many* Correspondence: lvyexu@126.com
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stated.evidences indicate that genotypic mutations at specific
amino acid positions in the HBV RT region would reduce
its susceptibility to NAs and HBV resistance, which
is now recognized as the single most important fac-
tor of virological breakthrough and failure treatment
of NAs [3-5].
At present, many mutations in the RT gene of HBV
have been reported to be associated with classical anti-
viral resistance, and mutations of rtA181, rtM204 and
rtN236 have been reported to be associated with major
primary drug resistance and are responsible for reduced
treatment susceptibility resulting from antiviral agentsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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from secondary and/or compensatory mutations such as
rtV173, rtL180 and rt250, which could restore the RT ac-
tivity defects of HBV caused by primary drug resistance
[6-9]. According to previously studies, the patterns of
genotypic resistance in the HBV polymerase can be cate-
gorized into five specific evolutionary pathways [10,11],
including L-nucleoside pathway (rtM204I [or V or I/V]),
the acyclic phosphonate pathway (rtN236T), the shared
pathway (rtA181T [or V or T/V]) of both L-nucleoside
and acyclic phosphonate, ETV resistance pathway
(rtL180M+rtM204V with one of either rtT184, S202 or
M250 residue changes) and multidrug resistance path-
ways (rtA181T+rtI233V+rtN236T+rtM250L).
However, the profile data of classical antiviral resistance
mutations belonging to different evolutionary pathways is
limited in real clinical practice. Thus, this study is designed
to characterize the molecular features of nucleos(t)ide
analogues resistance (NAr) mutation positions belonging
to different NAr pathways within HBV RT sequences.
Methods
Study design and patients
This was a population-based cross-sectional study. A total
of 1308 CHB patients undergoing LAM, ADV, ETV or
LdT treatment in single, sequential or combination be-
tween January 2008 and December 2012 were screened,
and only 179 patients with virological breakthrough were
finally included and analyzed in present study. The inclu-
sion criteria were CHB patients received NAs treatment
for more than 6 months and had virological breakthrough
with HBV DNA ≥ 1.0×104 copies/mL. The exclusion
criteria were patients with hepatitis C virus (HCV) or
human immunodeficiency virus (HIV) coinfection, auto-
immune liver disease and alcohol or drug abuse. This
study was also approved by the Ethics Committee of
Wuhan Neurologist Hospital and General Hospital of The
Yangtze River Shipping in accordance with the Declaration
of Helsinki.
Laboratory tests
Serum HBV DNA was quantified by fluorescence quan-
titative polymerase chain reaction (PCR) (Da’an Gene,
Guangzhou, China) with the lowest detection limit of
1,000 copies/mL. HBV gene fragment (nt54-1278)
encompassing the complete RT gene was amplified by
PCR. Sequencing was performed using the ABI 3730xl
DNA Analyzer(Hitachi, Tokyo, Japan). Sequencing data
were analyzed using the Vector NTI Suite software
package (Invitrogen, California, USA). HBV genotypes
assignment was based on the phylogenetic analysis of
the 1225-bp-long S/P-gene sequence (nt 54–1278) of
HBV genome. Mutations at 12 locations (including
rtL80, rtI169, rt173, rt180, rt181, rtT184, rtA194, rt202,rt204, rtI233, rt236, and rt250) in the RT gene belonging
to different NAr pathways were analyzed using DNAS-
tar version 5.0 (DNAStar, Madison, WI, USA) software,
and all above HBV NAs-resistant associated mutations
were detected when virological breakthrough occurred.
Definition
The clinical diagnosis of CHB was made according to
guideline on prevention and treatment of chronic hepatitis
B in China [12,13]. Virological breakthrough was defined
as having HBV DNA increase by >1 log from nadir level
or a re-detection of HBV DNA at levels at least 10-fold
higher than the lower limit of detection of the assay after
having an undetectable result [14].
Statistical analysis
Quantitative values expressed as mean plus standard de-
viation or range, and qualitative values were were pre-
sented as number and percent. Group comparisons
between qualitative values were performed using Chi-
square tests using SPSS 17.0 software (SPSS Inc., Chicago,
IL, United States). P value of less than 0.05 was considered
statistically significant.
Results
In this cohort, there were 63 (35.2%) females and 116
(64.8%) males with an average age of 38 years (range
21–63), and the HBeAg positivity rate was 67.6% (121/
179). Among those 179 HBV patients, 21.2% (38/179)
and 78.8% (141/179) were infected with HBV genotypes
B and C, respectively; 89.4% (160/179) of the patients
detected NAs-resistant mutations including 114 pa-
tients with LAM/LdT-based therapies and 46 patients
with ADV-based therapies. Among the 160 patients
with NAs-resistant mutations, up to 7 antiviral strat-
egies were involved which manifested as monotherapy
[LAM (n=72), ADV (n=41) or LdT (n=13)], LAM plus
ADV combination therapy (n=11), LAM switch-to ADV
(n=18), or ETV sequential therapies (n=5).
In present study, NAs associated mutations were de-
tected at positions rtL80, rtV173, rtL180, rtA181, rtS202,
rtM204, rtN236 and rtM250, but not at positions rtI169,
rtT184, rtA194 or rtI233. Among LAM/LdT-based treat-
ment (n=114), the prevalence rates of rtM204 mutations
were 100% (85/85), 77.8% (14/18), 50.0% (4/8) and 100%
(3/3) in patients receiving LAM or LdT monotherapy,
ADV switch-to, ADV add-on, or ETV switch-to therapy
respectively. And among those rtM204 mutations,
rtM204I, rtM204V and rtM204I/V accounted for 60.4%
(64/106), 31.1% (33/106) and 8.5% (9/106), respectively.
Thus, our finding further confirms that rtM204 should be
considered as an important primary LAM/LdT-resistance
mutation position in real clinical practice, and rtM204I
mutation is the most common type.
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of rtM204 containing mutant patterns were observed,
and rtM204I/V+rtL180M (78/106, 73.6%) and rtM204
I/V+rtL80I/V (48/106, 45.3%) were the two most com-
mon mutation patterns (Table 1). Compared with the
rtM204V mutants, the rtM204I mutants were preferen-
tially accompanied by the rtL80I/V mutations with a sta-
tistically significant difference [rtM204I+rtL80I/V (50.0%,
32/64) vs. rtM204V+rtL80I/V (27.3%, 9/33), P=0.032]. By
contrast, all rtM204V mutants were found to be coexistent
with rtL180M mutations, which was significantly higher
than that of rtM204I mutants [rtM204V+rtL180M (100%,
33/33) vs. rtM204I+rtL180M (60.9%, 39/64), P<0.001].
Among ADV-based treatment (n=46), the rtN236T
mutations were detected in 78% (32/41), 66.7% (2/3) and
50% (1/2) of patients receiving ADV monotherapy, LAM
add-on, or ETV switch-to therapies, respectively. Add-
itionally, among LAM/LdT-based monotherapy, 50% of
patients who (4/8) received ADV add-on also detected
rtN236T mutations.
Recently, HBV rtA181T/V mutations had been widely
concerned and it was regarded to be a multidrug resist-
ance which not only could result in resistance to ADV
but also reduce sensitivity to LAM and LdT. In this
cohort, HBV rtA181T/V mutation was observed in 19.3%
(22/114) of patients with LAM/LdT-based therapies and
23.9% (11/46) of patients with ADV-based therapies. It
was worth mentioning that this mutation was detected in
all 11 patients who received LAM plus ADV combination
therapy (8 from LAM/LdT-based combination therapyTable 1 The patterns of HBV rtM204 mutations in this
cohort
Types of mutation patterns Percentage
Combination mutation patterns including rtM204I 64
rtM204I+ rtL180M 26(40.6%)
rtM204I+ rtL80I/V 16(25.0%%)
rtM204I+ rtL80I/V+ rtL180M 7(10.9%)
rtM204I+ rtL80I/V+ rtA181T + rtM250L 5(7.8%)
rtM204I+ rtL180M + rtV173M 6(9.4%)
rtM204I+ rtL80I/V+ rtA181T 4(6.3%)
Combination mutation patterns including rtM204V 33
rtM204V+ rtL180M 15(45.5)
rtM204V+ rtV173L + rtL180M 9(27.3)
rtM204V+ rtL80I/V+ rtL180M 5(15.2)
rtM204V+ rtL80I/V + rtV173L + rtL180M 4(12.1)
Combination mutation patterns including rtM204I/V 9
rtM204I/V+ rtL80I/V++ rtA181T 3(33.3%)
rtM204I/V+ rtL180M+ rtA181T 2(22.2%)
rtM204I/V+ rtL80I/V+ rtL180M 3(33.3%)
rtM204I/V+ rtL80I/V+ rtV173L + rtL180M 1(11.1%)and 3 from ADV-based combination therapy). Our find-
ings suggested that rtA181T/V mutations were common
among patients with NAs resistance, and it should be
regularly monitored in real clinical practice.
Discussion
In this study, classical antiviral resistance mutations
within the HBV RT region, which belonged to diverse
evolutionary pathways, were analyzed among 179 CHB
patients with virological breakthrough. Among those pa-
tients, 89.4% (160/179) detected antiviral-resistant HBV
mutations, which indicated that the emergency of resist-
ance was the main reason for virological breakthrough
and failure of treatment. In this cohort, three classic evo-
lutionary pathways of L-nucleoside pathway against
LAM, LdT or ETV (rtM204 I/V), the acyclic phospho-
nate pathway (rtN236T) against ADV and the shared
pathway against both LAM and ADV (rtA181T T/V)
were all involved, and our findings were also supported
by recent studies [15,16]. Because tenofovir disoproxil
fumarate was currently unavailable in China, its associated
resistance mutations were not reported in this study.
Recently, rtI233 mutation has been reported to be as-
sociated with primary poor or failure response to ADV
[17]; however, this mutation was not observed in present
study. So we inferred that HBV rtI233 mutation was not
a common strain in real life of ADV-experienced pa-
tients and its clinical significance needs to be studied in
future. It has reported that rtA194T mutation was asso-
ciated with tenofovir (TDF), and it could be selected by
long-term application of ADV [18]. However, this muta-
tion was also not detected. Thus, we also thought that
HBV rtA194T might be not a common mutation induced
by ADV and TDF would be used as a rescue medication
for ADV treatment failure.
In this study, majority of patients had resistance that
was associated with the L-nucleoside pathway [rtM204I
(or V or I/V)], which could potentially lead to resistance
to LAM, ETV and LdT treatment in LAM-experienced
patients. The highest prevalence rate of genotypic resist-
ance to the L-nucleoside pathway was in agreement with
the largest percentage (66.3%, 106/160) of LAM-based
patients in our cohort. Indeed, this high prevalence of
rtM204 mutation was caused by the long-term use of
LAM in China. So we speculated the presence of rtM204
mutation carriers might constitute an unavoidable chal-
lenge for the effective control of antiviral-resistant HBV in
the future because it is difficult to clear such resistant viral
strains [19].
Although preliminary data using ADV belonging to
acyclic phosphonates on LAM-resistance patients seem
promising, a shared pathway (rtA181T/V) of both L-
nucleosides and acyclic phosphonates could be selected,
which would affect both LAM and ADV sensitivity [20].
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in 19.3% (22/114) of patients with LAM/LdT-based
therapy and 23.9% (11/46) of patients with ADV-based
therapy, and our results suggested that rtA181T/V anti-
viral resistance mutation has become a relatively common
phenomenon in Chinese patients. Thus, the potential risk
of the spread of such resistant viral strains (HBV rtM204
or rtA181mutants) is of therapeutic concern and repre-
sents a crucial public health threat [11,20].
The most obvious limitation of the study is its limited
sample size, thus clinical trials with large sample sizes
were required to reveal the comprehensive and accurate
profile of HBV resistance mutations against NAs.
Conclusions
Our findings indicate that there is a complex pool of re-
sistant HBV in real life of CHB patients with virological
breakthrough. Thus, monitoring HBV genotypic resistance
and shared resistant pathway pertaining to antiviral agents
would help to optimize or rescue current antiviral therap-
ies and avoid the outbreak of clinical deterioration.
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